Organon & Co. (NYSE:OGN) Issues Earnings Results, Misses Expectations By $0.02 EPS

Organon & Co. (NYSE:OGN) posted its quarterly earnings data on Friday. The company reported $0.85 EPS for the quarter, missing analysts’ consensus estimates of $0.87 by ($0.02), FiscalAI reports. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.

Organon & Co. Price Performance

OGN traded up $0.01 during trading on Friday, hitting $13.55. 2,689,351 shares of the stock traded hands, compared to its average volume of 6,106,729. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.60. The company has a market cap of $3.56 billion, a price-to-earnings ratio of 14.58, a PEG ratio of 1.25 and a beta of 1.54. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42. The business has a 50 day moving average price of $13.47 and a 200 day moving average price of $10.38.

Insider Buying and Selling at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of Organon & Co. stock in a transaction on Wednesday, May 6th. The shares were purchased at an average price of $13.35 per share, with a total value of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares in the company, valued at $705,560.85. This trade represents a 100.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On Organon & Co.

A number of institutional investors have recently modified their holdings of OGN. Royal Bank of Canada lifted its position in shares of Organon & Co. by 53.4% during the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock worth $5,374,000 after buying an additional 125,648 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Organon & Co. by 126.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock valued at $21,370,000 after buying an additional 801,307 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Organon & Co. by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock valued at $15,530,000 after purchasing an additional 26,640 shares during the last quarter. Focus Partners Wealth boosted its position in Organon & Co. by 33.2% in the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock valued at $832,000 after buying an additional 13,925 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Organon & Co. during the 2nd quarter valued at $107,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on OGN. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. BNP Paribas Exane reaffirmed a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and upped their price objective for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Finally, Weiss Ratings upgraded shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, July 13th. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.